Richard Schilsky

@rschilsky

I am a medical oncologist and the Principal Investigator of the American Society of Clinical Oncology TAPUR study. Tweets are my own.

Chicago, ILtapur.orgJoined March 2013

209 Following

9,333 Followers

Richard Schilsky’s Tweets

Richard Schilsky

@rschilsky

Great candidates to assure a bright future for

@SWOG

Quote Tweet

SWOG Cancer Research Network

@SWOG

Feb 3

Our @SWOGChair blog: Chair Searches: A Busy Week at SWOG! We welcome @marklewismd as new chair of @SWOG's digital engagement cmte, & our nominating cmte has chosen their ballot of candidates for @SWOG's upcoming group chair election. swog.org/news-events/ne

Proud to work with

to help Close the Care Gap! youtu.be/Inz3ZdnkaTw via

@YouTube

youtube.com

EORTC supports World Cancer Day 2023

This year's theme for World Cancer Day is “Close the Care Gap” and it is about reimagining a world where the lives of millions of people with cancer are save...

Richard Schilsky

@rschilsky

Feb 3

Larotrectinib available in ⁦

@ASCO

⁩ #TAPUR for NTRK amplified advanced solid tumors.

ascopubs.org

Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving...

PURPOSE Larotrectinib, a highly specific tropomyosin receptor kinase (TRK) inhibitor, previously demonstrated high response rates in single-arm trials of patients with TRK fusion-positive cancer, but...

Richard Schilsky

@rschilsky

Jan 31

Great project!

Quote Tweet

Raffaella Casolino

@Raffa_Casolino

Jan 30

Today we

a new @TheLancetOncol Commission in CancerGenomics & PrecisionOncology to

global access to innovative diagnostic tests/personalized care and

data sharing. See the article from SteeringCommittee & WG Leads thelancet.com/journals/lanon Stakeholders pls

to participate

Show this thread

Richard Schilsky

@rschilsky

Jan 27

I’m so excited to still have the opportunity to lead #TAPUR for

@ASCO

and to all who have supported it over the last 6.5 years.TAPUR Had Big Ambitions. Principal Investigator Dr. Richard L. Schilsky Discusses Its Success and Influence

dailynews.ascopubs.org

TAPUR Had Big Ambitions. Principal Investigator Dr. Richard L. Schilsky Discusses Its Success and...

Upon its launch in 2015, the TAPUR study employed a novel approach of evaluating additional uses of oncology drugs outside of indications already approved by the FDA. Six years later, it has expanded...

Richard Schilsky

@rschilsky

Jan 20

FDA OKs First Targeted Treatment for HER2-Positive Colorectal Cancer

medpagetoday.com

FDA OKs First Targeted Treatment for HER2-Positive Colorectal Cancer

Second-line tucatinib plus trastuzumab combo gets accelerated approval in metastatic disease

Working on this with

. Stay tuned!

Quote Tweet

Dr. Robert M. Califf

@DrCaliff_FDA

Jan 18

Our clinical research (evidence generation) system is too slow and expensive, leading to a vast gap between what we need to know about health interventions and what we actually know. journals.sagepub.com/eprint/EGDG82W

Show this thread

Richard Schilsky

@rschilsky

Dec 23, 2022

Precision immunotherapy!

Quote Tweet

Medscape Oncology

@MedscapeOnc

Dec 23, 2022

#FDAapproves first-in-class drug for follicular lymphoma ms.spr.ly/6015ebHRJ

Richard Schilsky

@rschilsky

Dec 23, 2022

Looking forward to Spring!

Richard Schilsky

@rschilsky

Dec 22, 2022

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer | NEJM

nejm.org

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer | NEJM

Original Article from The New England Journal of Medicine — Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

Richard Schilsky

@rschilsky

Dec 22, 2022

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C | NEJM

nejm.org

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C | NEJM

Original Article from The New England Journal of Medicine — Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

2023 forecast: FDA revamps cancer drug approvals, and Big Pharma is willing to fall in line

In what could represent a watershed moment in the FDA’s cancer drug practice, GSK pulled an accelerated approval for multiple myeloma drug Blenrep at the request of the FDA just 15 days after unvei |...

Richard Schilsky

@rschilsky

Dec 11, 2022

Gotta fix this!! Eligibility criteria more likely to exclude minorities from lymphoma clinical trials

healio.com

Eligibility criteria more likely to exclude minorities from lymphoma clinical trials

Up to one-quarter of those seeking clinical trial enrollment for novel front-line therapies to treat diffuse large B-cell lymphoma are excluded based on organ function laboratory values, study...

Richard Schilsky

@rschilsky

Dec 10, 2022

Recommendations From Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan ja.ma/3WorYGv via

@JAMANetworkOpen

part of

@JAMANetwork

jamanetwork.com

Recommendations From Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan

This quality improvement study compares concordance between the recommendations for cancer treatment between independent molecular tumor boards and a central committee.

Great seeing ⁦

⁩ at ⁦⁦

⁩ foundation Innovation in Regulatory Science Awards dinner last night. Looking forward to working closely with him to advance ⁦

⁩ mission.

The VALID Act is important to insure that the right patient gets the right drug based on results of a high quality test!

statnews.com

Congress needs to update FDA's ability to regulate diagnostic tests, cosmetics

The FDA is currently working from an outdated regulatory playbook for diagnostic tests and cosmetics that has left gaps in its oversight of safety and effectiveness.

Richard Schilsky

@rschilsky

Dec 5, 2022

Collateral lethality in cancer target selection, fascinating!

nature.com

Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian...

Nature Metabolism - Achreja et al. develop a framework to identify collateral lethalities in cancer, uncovering MTHFD2 as a collateral lethal gene in UQCR11-deficient ovarian tumours.

Richard Schilsky

@rschilsky

Dec 3, 2022

Genomic testing a key part of cancer care.

nejm.org

Closing the Gap in Cancer Genomic Testing | NEJM

Perspective from The New England Journal of Medicine — Closing the Gap in Cancer Genomic Testing

Richard Schilsky

@rschilsky

Nov 30, 2022

Better lab test standards can ensure precision medicine is truly precise statnews.com/2022/11/30/val via

@statnews

statnews.com

Better lab test standards can ensure precision medicine is truly precise

An individual's best chance to fight cancer or other life-threatening disease should never be affected by something as easily preventable as a faulty diagnostic test.

Richard Schilsky

@rschilsky

Nov 30, 2022

Prognostic Value of FLT3 Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia

ascopubs.org

Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia

PURPOSE The applicability of FLT3-internal tandem duplications (FLT3-ITD) for assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission (CR) has been hampered...

Richard Schilsky

@rschilsky

Nov 30, 2022

Prior Authorization Linked to Cancer Progression and Death

cancertherapyadvisor.com

Prior Authorization Linked to Cancer Progression and Death

The prior authorization process can delay cancer care, leading to disease progression and death, according to a survey of ASCO members.

Richard Schilsky

@rschilsky

Nov 27, 2022

We need to fix this! This is biology's century. We're not ready for it

statnews.com

Here’s why we’re not prepared for the next wave of biotech innovation

This is "biology's century," @matthewherper writes. But we’re approaching a moment when changes in what we understand are every bit as terrifying as exhilarating.

CRISPR vs breast, colon, lung cancer: First human trial goes well

A small human trial has tested CRISPR gene editing technology in the treatment of solid cancer tumors, including breast, colon, and lung cancer, with promising results.

Richard Schilsky

@rschilsky

Nov 22, 2022

Great resource!

Quote Tweet

Foundation for FDA

@reaganudall

Nov 22, 2022

#ExpandedAccess may be considered for patients who have exhausted their treatment options and are not eligible for, or able to participate in, a clinical trial. The EA Navigator has information you need to discuss EA with your physician: loom.ly/nq5_m6E

Richard Schilsky

@rschilsky

Nov 18, 2022

NCI "new normal" for clinical trials long overdue.

cancerletter.com

A “new normal” for NCI-sponsored clinical trials is long overdue - The Cancer Letter

I read with interest the recently published story on the recommendations to streamline data collection in certain NCI trials presented at the Nov. 9, 2022, meeting of the Clinical and Translational...

Richard Schilsky

@rschilsky

Nov 18, 2022

Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort

ascopubs.org

Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiv...

PURPOSE Mitogen-activating protein kinase inhibitors (MAPKis) are largely used in V600E/K BRAF–mutated metastatic melanomas, but data regarding effectiveness of targeted therapy in patients with rare...

Richard Schilsky

@rschilsky

Nov 18, 2022

Need more studies like this one! Adoption and Comparative Effectiveness of Extended-Interval Pembrolizumab ja.ma/3XiBmN8 via

@JAMAOnc

part of

@JAMANetwork

jamanetwork.com

Adoption and Comparative Effectiveness of Extended-Interval Pembrolizumab

This retrospective cohort study examines adoption and real-world effectiveness of extended-interval pembrolizumab among a cohort of more than 800 US veterans being treated with single-agent pembrol...

Richard Schilsky

@rschilsky

Nov 18, 2022

Need to get back on track with cancer screenings! Cancer diagnoses lag after screenings fall during pandemic, U.S. study finds

reuters.com

Cancer diagnoses lag after screenings fall during pandemic, U.S. study finds

Screenings for a variety of common cancers have not returned to pre-pandemic levels, potentially leading to diagnoses later in the course of the disease when it may be more difficult to treat...

Richard Schilsky

@rschilsky

Nov 16, 2022

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

ascopubs.org

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III...

PURPOSE Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to whether early...

Richard Schilsky Retweeted

JAMA Oncology

@JAMAOnc

Nov 16, 2022

Post-marketing data reported to

@US_FDA

identifies colitis associated with alelisib use among 20 female patients, leading to increased enhancing clinician awareness & promote early recognition & potential treatment for patients on this agent. ja.ma/3eNRV1Y

Prevalence of Mismatch-Repair Deficiency in Rectal Adenocarcinomas | NEJM

Correspondence from The New England Journal of Medicine — Prevalence of Mismatch-Repair Deficiency in Rectal Adenocarcinomas

Richard Schilsky

@rschilsky

Nov 11, 2022

About time...NCI following

@ASCO

#TAPUR lead to simplify clinical trials! It can be done!!

cancerletter.com

NCI’s Doroshow: “These recommendations are something that we can implement right away” - The Cancer...

NCI will immediately start the process of streamlining IND-exempt trials in order to make them faster, simpler, more flexible, less expensive, and easier to integrate with clinical practice, James...

Richard Schilsky

@rschilsky

Nov 6, 2022

Woman diagnosed with 12 tumors in her lifetime has a never-before-seen genetic mutation

livescience.com

Woman diagnosed with 12 tumors in her lifetime has a never-before-seen genetic mutation

A woman who's incredibly prone to tumors carries an unusual genetic mutation.

Richard Schilsky

@rschilsky

Nov 5, 2022

Exciting new hypothesis…

Quote Tweet

WIN Consortium

@WIN_Consortium

Nov 4, 2022

@WIN_Consortium's transcriptomic data has identified a normal immune-tolerant state, that may explain a potential comorbidity risk between 2 diseases #NSCLC and susceptibility to #COVID-19 pneumonia journals.sagepub.com/doi/10.1177/17 @Vlad_Lazar_WIN @rschilsky @TaberneroJosep @Dr_R_Kurzrock